KURA ONCOLOGY INC
KURANASDAQTrading Snapshot
- Day Range
- $9.88 – $10.03
- 52-Week Range
- $5.45 – $12.49
- Volume
- $1.94B
- Avg Volume
- $2.42B
- Shares Outstanding
- 88.8M
- Next Earnings
- Aug 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- 11.9x
- EPS (TTM)
- $-3.35
- Dividend Yield
- —
Why Investors Own KURA
- ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About KURA ONCOLOGY INC
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Kura Oncology Announces Publication Of Manuscript In Blood, Journal Of The American Society Of Hematology, Detailing Discovery And Preclinical Development Of Ziftomenib
– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –– Findings demonstrate differentiated menin binding and activity against
Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma - Slideshow
2026-07-29. The following slide deck was published by Kura Oncology, Inc.
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.
Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma Transcript
Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma July 27, 2026 8:00 AM EDTCompany...
Kura Oncology Announces Updated Phase 1A Results From Ongoing FIT-001 Clinical Trial; Data Demonstrate Encouraging And Durable Clinical Activity Of Darlifarnib Plus Cabozantinib In Cabozantinib-Naïve Patients With Advanced Clear Cell Renal Cell Carcinoma
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –– Activity compares favorably with
A Fresh Look At Syndax Pharmaceuticals
Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.